WASHINGTON, D.C. (March 12, 2003) – The Biotechnology Industry Organization (BIO) and the California Healthcare Institute (CHI) will host a breakfast, panel briefing tomorrow, Thursday, March 13, to discuss how payment cuts within the Medicare program are threatening access to important biotech medicines for the nation’s elderly and disabled populations.
||David Gollaher, Ph.D., president and CEO, CHI
David Pyott, chairman, president and CEO, Allergan
Sean Lance, chairman and CEO, Chiron
Myrtle Potter, executive vice president, commercial operations and COO, Genentech
Chuck Howe, vice president, sales, IDEC Pharmaceuticals
Diane Dorman, vice president of public policy, National Organization for Rare Disorders
Rosalie Lewis, president, Dystonia Medical Research Foundation
Pedro Vergne-Marini, M.D., F.A.C.P., F.A.C.C., Methodist Hospital
Ken McKusick, M.D., F.A.C.N.P., F.A.C.R., Society of Nuclear Medicine
Beth Roberts, partner, Health Group, Hogan and Hartson
Don Moran, The Moran Group
Sharon Cohen, vice president, government relations, BIO
||A panel discussion on how changes within the Medicare reimbursement structure for hospital outpatient services, which went into effect Jan. 1, 2003, hinder patient access to new, innovative biotech medicines. Breakfast will be served during the event.
||Thursday, March 13, 9:00 a.m. to 10:30 a.m.
||Room H-137, Capitol Building
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.
CHI is a non-profit public policy research organization for California’s biomedical industry. Its coalition of more than 225 biotechnology, medical device and pharmaceutical companies, and academic research organizations strives to advance responsible public policies that foster medical innovation and promote scientific discovery.